Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia
Authors:
- M. I. RestrepoMRM. I. Restrepo
- E. M. MortensenEME. M. Mortensen
- G. W. WatererGWG. W. Waterer
- R. G. WunderinkRWR. G. Wunderink
- J. J. CoalsonJCJ. J. Coalson
- A. AnzuetoAAA. Anzueto
- 3 September 2008
- journal article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 33 (1) , 153-159
Abstract
Recent studies suggest that macrolides may have beneficial effects for patients at risk for certain infections. The current authors examined the effect of macrolide therapy on 30- and 90-day mortality for patients with severe sepsis caused by pneumonia.A retrospective cohort study was conducted at two tertiary teaching hospitals. Eligible subjects were admitted with a diagnosis of, had chest radiography consistent with, and had a discharge diagnosis of pneumonia and clinical criteria of severe sepsis. Subjects were considered to be on macrolides if they received at least one dose within 48 h of admission.Severe sepsis was present in 237 (30.1%) subjects, out of whom 104 (43.9%) received macrolides. Mortality was 20.3% at 30 days and 24.5% at 90 days. In the multivariable analysis, the use of macrolide was associated with decreased mortality at 30 days (hazard ratio (HR) 0.3, 95% confidence interval (CI) 0.2–0.7) and at 90 days (HR 0.3, 95% CI 0.2–0.6) in patients with severe sepsis and in patients with macrolide-resistant pathogens (HR 0.1, 95% CI 0.02–0.5).Macrolide use was associated with decreased mortality in patients with severe sepsis due to pneumonia and macrolide-resistant pathogens. Confirmatory studies are needed to determine whether macrolide therapy may be protective for patients with sepsis.Keywords
This publication has 25 references indexed in Scilit:
- Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008Critical Care Medicine, 2008
- Modulation of neutrophil and inflammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatmentEuropean Journal of Pharmacology, 2005
- Anti-inflammatory effects of macrolides—an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?Journal of Antimicrobial Chemotherapy, 2005
- Combination Antibiotic Therapy Lowers Mortality among Severely Ill Patients with Pneumococcal BacteremiaAmerican Journal of Respiratory and Critical Care Medicine, 2004
- Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosisJournal of Antimicrobial Chemotherapy, 2004
- Immunomodulatory Clarithromycin Treatment of Experimental Sepsis and Acute Pyelonephritis Caused by Multidrug-Resistant Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2004
- The Epidemiology of Sepsis in the United States from 1979 through 2000New England Journal of Medicine, 2003
- Addition of a Macrolide to a β‐Lactam–Based Empirical Antibiotic Regimen Is Associated with Lower In‐Hospital Mortality for Patients with Bacteremic Pneumococcal PneumoniaClinical Infectious Diseases, 2003
- Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of careCritical Care Medicine, 2001
- Efficacy and Safety of Recombinant Human Activated Protein C for Severe SepsisNew England Journal of Medicine, 2001